source
- Replimune secures FDA approval for Tudriqev, eyes $1.3 bn peak sales in advanced melanomaReplimune announced FDA approval of its therapy Tudriqev for patients with advanced melanoma who have progressed after PD-1 treatment. Analysts at BMO Capital Markets project the drug could genera…
- Senate introduces BINSA bill to tighten review of China biotech and pharma transactionsThe U.S. Senate has introduced the Biotech Innovation and National Security Act (BINSA), a bill that would tighten oversight of biotech and pharmaceutical transactions involving China. The proposa…